Hansa Medical AB

May 02, 2019

Hansa Biopharma Announces Upcoming Presentations at the 2019 American Transplant Congress

Apr 15, 2019

Hansa Biopharma Receives Ethics and Regulatory Clearance to Start Phase 2 Study of Imlifidase in Guillain Barré Syndrome

Mar 26, 2019

Hansa Biopharma Receives Ethics and Regulatory Clearance to Start Phase 2 Study of Imlifidase in Acute Antibody Mediated Rejection in Kidney Transplantation

Mar 21, 2019

Hansa Biopharma Announces Selection of NiceR Lead Candidate

Mar 01, 2019

Hansa Biopharma Announces European Medicines Agency Accepts Marketing Authorization Application for IDEFIRIX(TM) (imlifidase)

Jan 15, 2019

Hansa Medical AB Provides Regulatory Update for Imlifidase in Kidney Transplantation

Dec 20, 2018

Hansa Medical AB to Change Name to Hansa Biopharma AB

Dec 11, 2018

Bulletin from the Extraordinary General Meeting of Hansa Medical AB (publ)

Nov 21, 2018

Hansa Medical AB to Present at the Evercore ISI HealthConX Conference

Sep 27, 2018

Hansa Medical Reports Positive Final Top Line Results from Two Phase 2 Studies of Imlifidase for Kidney Transplantation